Globus Medical, Inc.
NYSE:GMEDMedical - Devices
-$2.10 today
- Market cap
- $9.34B
- Beta
- 0.95
- P/E (TTM)
- 17.4
- EPS (TTM)
- $4.33
Volume 1.43M
Average 1.45M
GMED Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Globus Medical, Inc.NYSE: GMED
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue dips below year-ago levels
Q2 FY2026 cost of revenue of $241.44M fell 2.9% year over year, behind the +1.1% change in trailing-twelve-month cost of revenue. Sequentially, it rose 3.1% from the prior quarter. Over 3 fiscal years it compounded at +53.7% a year.
Context
- Cost of revenue amounted to 32.6% of revenue in FY2025, down 8.5 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -2.9% toward the trailing-twelve-month pace of +1.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 957.8M USD
- Year-over-year change
- -7.5%
- 4-year CAGR
- +41.5%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 957.8M | -7.5% |
| FY2024 | 2024-12-31 | 1.04B | +88.9% |
| FY2023 | 2023-12-31 | 548.17M | +107.9% |
| FY2022 | 2022-12-31 | 263.73M | +10.2% |
| FY2021 | 2021-12-31 | 239.22M | — |
Cost of Revenue vs competitors
How GMED compares with its peers on the latest reported figures
- GMED's LTM Jun 2026 cost of revenue of $989.14M is the 4th highest of the 10 companies compared; the peer median is $255.74M.
- Its year-over-year change of +1.1% is the 7th highest of 10, against a peer median of +13.1%.
- Cost of revenue amounts to 31.5% of revenue for GMED, versus a peer median of 31.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $9B | +1.8% | +6.9% | 34.8% | |
| LTM Jun 2026 | $2.56B | +13.1% | +16.1% | 30.1% | |
| FY2025 | $1.96B | +13.1% | +8.9% | 31.7% | |
| LTM Jun 2026 | $989.14M | +1.1% | +53.7% | 31.5% | |
| LTM Mar 2026 | $272.95M | +36.9% | +25.4% | 34.7% | |
| LTM Mar 2026 | $255.74M | -3.2% | +29.9% | 31.0% | |
| LTM Mar 2026 | $185.67M | -0.4% | +0.8% | 32.2% | |
| LTM Mar 2026 | $65.51M | +13.4% | +26.3% | 26.9% | |
| LTM Mar 2026 | $45.91M | -10.2% | +24.3% | 37.7% | |
| LTM Mar 2026 | $42.1M | +14.9% | +37.7% | 20.4% | |
| Peer median (excluding GMED) | $255.74M | +13.1% | +24.3% | 31.7% | |
Competitors are the stored peer set for GMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 958.1M | 1.02B | 1.57B | 2.52B | 2.94B |
| Cost of Revenue | 239.22M | 263.73M | 548.17M | 1.04B | 957.8M |
| Gross Profit | 718.88M | 759.12M | 1.02B | 1.48B | 1.98B |
| Gross Margin | 75.0% | 74.2% | 65.1% | 58.9% | 67.4% |
| Research & Development | 97.35M | 73.02M | 124.01M | 163.75M | 185M |
| Selling, General & Admin | 408.15M | 432.12M | 643.41M | 981.05M | 1.32B |
| Operating Expenses | 546.93M | 531.17M | 887.16M | 1.32B | 1.5B |
| Depreciation & Amortization | 69.87M | 68.25M | 144.73M | 254.02M | 276.84M |
| EBITDA | 264.73M | 304.5M | 346.58M | 473.73M | 886.74M |
| EBITDA Margin | 27.6% | 29.8% | 22.1% | 18.8% | 30.2% |
| Operating Income | 171.95M | 227.95M | 133.14M | 165.99M | 479.8M |
| Operating Margin | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% |
| Interest Income | 9.3M | 14.23M | 20.13M | 0 | 7.14M |
| Interest Expense | 0 | 0 | 0 | 4.19M | 0 |
| Other Income / Expenses | 8.45M | 15.07M | 32.25M | (45.27M) | 130.1M |
| Income Before Tax | 180.41M | 243.02M | 165.39M | 120.72M | 609.9M |
| Pre-Tax Margin | 18.8% | 23.8% | 10.5% | 4.8% | 20.8% |
| Income Tax Expense | 31.22M | 52.85M | 42.52M | 17.74M | 72M |
| Net Income | 149.19M | 190.17M | 122.87M | 102.98M | 537.9M |
| Net Margin | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% |
| EPS (Basic) | 1.48 | 1.89 | 1.09 | 0.76 | 3.98 |
| EPS (Diluted) | 1.44 | 1.85 | 1.07 | 0.75 | 3.92 |
| Weighted Avg Shares | 100.73M | 100.47M | 113.09M | 135.73M | 135.15M |
| Weighted Avg Shares (Diluted) | 103.62M | 102.64M | 114.63M | 137.86M | 137.22M |
Globus Medical, Inc.
NYSE:GMED
Intrinsic Alpha fair value
Locked
Current Price
$70.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.